INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis

J Cohen, J Carlet - Critical care medicine, 1996 - journals.lww.com
Objective To determine the safety and efficacy of BAY times 1351, a murine monoclonal
antibody to recombinant human tumor necrosis factor (TNF)-alpha, in patients with sepsis.
Design An international, multicenter, prospective, placebo-controlled trial in patients with
sepsis, stratified into shock/nonshock groups. Setting